Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2026)

Top biotech stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Xeris Biopharma Holdings (NASDAQ:XERS) is the #1 top biotech stock out of 607 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Xeris Biopharma Holdings (NASDAQ:XERS) is: Value: C, Growth: A, Momentum: A, Sentiment: A, Safety: C, Financials: B, and AI: B.

Xeris Biopharma Holdings (NASDAQ:XERS) has a Due Diligence Score of 39, which is 15 points higher than the biotech industry average of 24.

XERS passed 13 out of 33 due diligence checks and has average fundamentals. Xeris Biopharma Holdings has seen its stock return 129.48% over the past year, overperforming other biotech stocks by 225 percentage points.

Xeris Biopharma Holdings has an average 1 year price target of $17.00, an upside of 2.04% from Xeris Biopharma Holdings's current stock price of $16.66.

Xeris Biopharma Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Xeris Biopharma Holdings, 20% have issued a Strong Buy rating, 60% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Regeneron Pharmaceuticals (NASDAQ:REGN) is the #2 top biotech stock out of 607 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Regeneron Pharmaceuticals (NASDAQ:REGN) is: Value: B, Growth: B, Momentum: B, Sentiment: A, Safety: B, Financials: B, and AI: B.

Regeneron Pharmaceuticals (NASDAQ:REGN) has a Due Diligence Score of 47, which is 23 points higher than the biotech industry average of 24.

REGN passed 18 out of 38 due diligence checks and has strong fundamentals. Regeneron Pharmaceuticals has seen its stock return 37.48% over the past year, overperforming other biotech stocks by 133 percentage points.

Regeneron Pharmaceuticals has an average 1 year price target of $904.29, a downside of -5.36% from Regeneron Pharmaceuticals's current stock price of $955.47.

Regeneron Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 24 analysts covering Regeneron Pharmaceuticals, 58.33% have issued a Strong Buy rating, 8.33% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Fennec Pharmaceuticals (NASDAQ:FENC) is the #3 top biotech stock out of 607 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Fennec Pharmaceuticals (NASDAQ:FENC) is: Value: C, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Fennec Pharmaceuticals (NASDAQ:FENC) has a Due Diligence Score of 50, which is 26 points higher than the biotech industry average of 24.

FENC passed 17 out of 33 due diligence checks and has strong fundamentals. Fennec Pharmaceuticals has seen its stock return 51.11% over the past year, overperforming other biotech stocks by 147 percentage points.

Fennec Pharmaceuticals has an average 1 year price target of $16.67, an upside of 43.43% from Fennec Pharmaceuticals's current stock price of $11.62.

Fennec Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Fennec Pharmaceuticals, 33.33% have issued a Strong Buy rating, 66.67% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 8 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Rallybio (NASDAQ:RLYB) has an annual dividend yield of 86.26%, which is 73 percentage points higher than the biotech industry average of 12.82%.

Rallybio's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Oramed Pharmaceuticals (NASDAQ:ORMP) has an annual dividend yield of 6.74%, which is -6 percentage points lower than the biotech industry average of 12.82%.

Oramed Pharmaceuticals's dividend payout ratio of 7.1% indicates that its high dividend yield is sustainable for the long-term.

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 4.45%, which is -8 percentage points lower than the biotech industry average of 12.82%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 48.3% indicates that its high dividend yield is sustainable for the long-term.

Biotech stocks were down -0.68% in the last day, and up 0.7% over the last week. Oragenics was the among the top losers in the biotechnology industry, dropping -42.86% yesterday.

Oragenics shares are trading lower. The stock initially rallied yesterday after the company announced it had been granted an extension to regain NYSE compliance, but it has since reversed.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 57, which is 42 points higher than the biotech industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -1.55% in the past year. It has overperformed other stocks in the biotech industry by 94 percentage points.

Innoviva (NASDAQ:INVA) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Innoviva has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Innoviva's stock has dropped -14.28% in the past year. It has overperformed other stocks in the biotech industry by 81 percentage points.

Zevra Therapeutics (NASDAQ:ZVRA) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Zevra Therapeutics has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Zevra Therapeutics's stock has dropped -1.63% in the past year. It has overperformed other stocks in the biotech industry by 94 percentage points.

63% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 80.07% over the next year.

2.25% of biotech stocks have a Zen Rating of A (Strong Buy), 3.83% of biotech stocks are rated B (Buy), 44.82% are rated C (Hold), 36.71% are rated D (Sell), and 12.39% are rated F (Strong Sell).